Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $357.00 by Analysts at Needham & Company LLC

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target cut by equities researchers at Needham & Company LLC from $510.00 to $357.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s price target indicates a potential upside of 77.54% from the stock’s previous close.

ALNY has been the subject of several other research reports. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Truist Financial lowered their price objective on Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a research report on Monday, July 13th. JPMorgan Chase & Co. cut their target price on shares of Alnylam Pharmaceuticals from $420.00 to $400.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 22nd. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 25th. Finally, Citigroup started coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $445.48.

Alnylam Pharmaceuticals Stock Down 29.8%

Shares of NASDAQ ALNY traded down $85.54 during mid-day trading on Thursday, hitting $201.08. The company had a trading volume of 6,977,809 shares, compared to its average volume of 1,339,297. The company has a market capitalization of $26.85 billion, a PE ratio of 55.17 and a beta of 0.27. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. Alnylam Pharmaceuticals has a 1-year low of $199.88 and a 1-year high of $495.55. The business’s 50-day simple moving average is $291.70 and its 200 day simple moving average is $313.42.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same period last year, the business posted ($0.51) earnings per share. Alnylam Pharmaceuticals’s revenue was up 66.9% compared to the same quarter last year. On average, analysts predict that Alnylam Pharmaceuticals will post 7.35 earnings per share for the current year.

Insider Activity

In other news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Assenagon Asset Management S.A. boosted its stake in Alnylam Pharmaceuticals by 20.8% in the second quarter. Assenagon Asset Management S.A. now owns 155,695 shares of the biopharmaceutical company’s stock valued at $46,869,000 after acquiring an additional 26,799 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 7.9% during the first quarter. Parallel Advisors LLC now owns 891 shares of the biopharmaceutical company’s stock worth $295,000 after purchasing an additional 65 shares in the last quarter. Glenmede Trust Co. NA increased its position in shares of Alnylam Pharmaceuticals by 8.3% during the first quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 56 shares in the last quarter. Groupama Asset Managment lifted its holdings in shares of Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Groupama Asset Managment now owns 36,767 shares of the biopharmaceutical company’s stock valued at $12,165,000 after purchasing an additional 889 shares during the last quarter. Finally, Segall Bryant & Hamill LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at about $641,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported second-quarter revenue of approximately $1.29 billion, up 66.9% from the prior-year period, while EPS improved to $1.84 from $0.32 a year earlier. One analyst benchmark viewed EPS as above its $1.63 estimate. Alnylam earnings report
• Positive Sentiment: New Alzheimer’s RNA-interference data and quarterly revenue exceeding $1 billion had recently supported optimism about Alnylam’s pipeline and commercial growth potential. A valuation analysis also suggested the shares could be undervalued if the pipeline advances successfully. Alnylam Alzheimer’s RNAi data
• Neutral Sentiment: Management issued fiscal 2026 revenue guidance of $5.3 billion to $5.7 billion, broadly near the $5.6 billion consensus forecast. However, the provided update did not include a clearly stated EPS outlook, limiting visibility for investors.
• Negative Sentiment: Quarterly revenue of $1.29 billion fell short of the approximately $1.32 billion consensus estimate. Zacks also reported EPS of $1.84 below its $2.05 estimate, creating confusion across earnings benchmarks but reinforcing concerns that the quarter did not fully meet expectations. Alnylam Q2 earnings miss
• Negative Sentiment: The market reaction suggests investors were looking for stronger execution or guidance, particularly after Alnylam’s substantial prior gains. The revenue miss and lack of a clearly disclosed EPS forecast outweighed the company’s strong growth and positive clinical developments.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.